



# Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach

Laura M. Güdemann<sup>1</sup> · Katie G. Young<sup>1</sup> · Nicholas J. M. Thomas<sup>1</sup> · Rhian Hopkins<sup>1</sup> · Robert Challen<sup>1</sup> · Angus G. Jones<sup>1</sup> · Andrew T. Hattersley<sup>1</sup> · Ewan R. Pearson<sup>2</sup> · Beverley M. Shields<sup>1</sup> · Jack Bowden<sup>1</sup> · John M. Dennis<sup>1</sup> · Andrew P. McGovern<sup>1</sup> · on behalf of the MASTERMIND consortium

Received: 15 January 2024 / Accepted: 11 March 2024  
© The Author(s) 2024

## Abstract

**Aims/hypothesis** Older adults are under-represented in trials, meaning the benefits and risks of glucose-lowering agents in this age group are unclear. The aim of this study was to assess the safety and effectiveness of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in people with type 2 diabetes aged over 70 years using causal analysis.

**Methods** Hospital-linked UK primary care data (Clinical Practice Research Datalink, 2013–2020) were used to compare adverse events and effectiveness in individuals initiating SGLT2i compared with dipeptidyl peptidase-4 inhibitors (DPP4i). Analysis was age-stratified: <70 years (SGLT2i  $n=66,810$ , DPP4i  $n=76,172$ ),  $\geq 70$  years (SGLT2i  $n=10,419$ , DPP4i  $n=33,434$ ). Outcomes were assessed using the instrumental variable causal inference method and prescriber preference as the instrument.

**Results** Risk of diabetic ketoacidosis was increased with SGLT2i in those aged  $\geq 70$  (incidence rate ratio compared with DPP4i: 3.82 [95% CI 1.12, 13.03]), but not in those aged <70 (1.12 [0.41, 3.04]). However, incidence rates with SGLT2i in those  $\geq 70$  was low (29.6 [29.5, 29.7]) per 10,000 person-years. SGLT2i were associated with similarly increased risk of genital infection in both age groups (incidence rate ratio in those <70: 2.27 [2.03, 2.53];  $\geq 70$ : 2.16 [1.77, 2.63]). There was no evidence of an increased risk of volume depletion, poor micturition control, urinary frequency, falls or amputation with SGLT2i in either age group. In those  $\geq 70$ , HbA<sub>1c</sub> reduction was similar between SGLT2i and DPP4i (−0.3 mmol/mol [−1.6, 1.1], −0.02% [0.1, 0.1]), but in those <70, SGLT2i were more effective (−4 mmol/mol [4.8, −3.1], −0.4% [−0.4, −0.3]).

**Conclusions/interpretation** Causal analysis suggests SGLT2i are effective in adults aged  $\geq 70$  years, but increase risk for genital infections and diabetic ketoacidosis. Our study extends RCT evidence to older adults with type 2 diabetes.

**Keywords** Causal analysis · Effectiveness · Older adults · Safety · SGLT2 inhibitors

## Abbreviations

AE	Adverse event	EMA	European Medicines Agency
CPRD	Clinical Practice Research Datalink	FDA	U.S. Food and Drug Administration
DKA	Diabetic ketoacidosis	HES	Hospital Episode Statistics
DPP4i	Dipeptidyl peptidase-4 inhibitors	IR	Incidence rate
		IRR	Incidence rate ratio
		SGLT2i	Sodium–glucose cotransporters 2 inhibitors

John M. Dennis and Andrew P. McGovern are joint senior authors.

✉ Laura M. Güdemann  
l.guedemann@exeter.ac.uk

<sup>1</sup> Institute of Biomedical & Clinical Science, University of Exeter Medical School, Exeter, UK

<sup>2</sup> Division of Molecular & Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK

## Research in context

### What is already known about this subject?

- Guidelines for type 2 diabetes recommend an individualised approach to treatment and sodium–glucose cotransporter 2 inhibitors (SGLT2i) are recommended for specific patient subgroups based on the individual cardiorenal disease profile
- However, evidence for older adults is limited as this patient group is often excluded from trials due to strict exclusion criteria and common comorbidities
- Observational studies assessing the effectiveness and safety of SGLT2i are rare and do not take inherent bias due to unmeasured confounding into account

### What is the key question?

- How effective and safe are SGLT2i in the subgroup of older people with type 2 diabetes (70 years and above) for which clinical trial evidence is rare?

### What are the new findings?

- SGLT2i are effective in reducing HbA<sub>1c</sub> and weight and are generally safe for older adults
- Adverse events of concern in this older group include genital infections and a small increase in diabetic ketoacidosis

### How might this impact on clinical practice in the foreseeable future?

- SGLT2i are effective and safe for older adults, but clinicians should be aware of the risks for genital infections and diabetic ketoacidosis

## Introduction


Current type 2 diabetes guidelines recommend an individualised approach to treatment that takes into account preferences, comorbidities, risks from polypharmacy, and the likelihood of long-term benefit from interventions [1, 2], but clear guidance on therapeutic strategies for the management of type 2 diabetes in older adults is limited [3]. For older adults, specific treatment considerations are likely to be needed, due to increased comorbidities, age-related changes in physiology and pharmacodynamics, as well as possible increased propensity to adverse medication effects.

Under current guidelines, a large proportion of older people with type 2 diabetes would be recommended sodium–glucose cotransporters 2 inhibitors (SGLT2i) due to their cardiorenal benefits, and irrespective of their glycaemic control [1, 4]. SGLT2i have well described benefits, particularly cardiorenal benefits and the promotion of weight loss [5–8], but also possible risks, which may limit their use for older people [3]. Well-established risks of SGLT2i are genital infections and, due to their mode of action, volume depletion is possible [6, 9]. These side effects could be of particular concern for older adults where incontinence, dehydration and dizziness could have more severe consequences compared with a younger population [10–13]. Additionally, dehydration or dizziness can also lead to falls in

older people [14]. Further adverse events (AEs) of concern of SGLT2i are lower limb amputations [9]. Reports of possible association of SGLT2i and diabetic ketoacidosis (DKA) has prompted the U.S. Food and Drug Administration (FDA) [15] and the European Medicines Agency (EMA) [16] to issue warnings. Older people may also present with more frequent acute complications, such as infections, which are additional risk factors of DKA [17].

In order to develop targeted guidelines for the management of type 2 diabetes in older adults, evidence on risks and benefits of treatments in this age group is needed [3]. However, older people are under-represented in RCTs and caution is needed when extrapolating RCT evidence for this group [3, 18]. Observational studies of the older type 2 diabetes population have the potential to provide insights that are not provided by RCTs. Previous post hoc RCT analyses [13, 19–21] have examined risks in older adults, but have very small sample size for older people with type 2 diabetes, and therefore might suffer from outlier effects [13]. Also, without detailed data on characteristics, comorbidities and concomitant medications, the results from observational studies may be affected by unmeasured confounding which can bias treatment effect results [14].

We therefore aimed to examine the relative risks and benefits of SGLT2i in older people compared with dipeptidyl peptidase-4 inhibitors (DPP4i) using large-scale



**Fig. 1** Flow chart of study cohort selection, stratified by age

routine primary and linked secondary care data. We employ an instrumental variable approach, exploiting systematic variation in practitioners' prescribing preference as the instrument, to estimate the impact of receiving SGLT2i compared with DPP4i on a range of AEs and important treatment outcomes, analogous to an RCT.

## Methods

### Study design and participants

In this retrospective cohort study, UK routine primary care data were accessed from Clinical Practice Research Datalink (CPRD) Aurum (October 2020 download). CPRD is a UK representative sample covering approximately 13% of the

population in England [22]. CPRD Aurum was linked to Hospital Episode Statistics (HES), Office for National Statistics (ONS) death registrations and individual-level Index of Multiple Deprivation (IMD). Individuals with type 2 diabetes were identified according to a previously published protocol [23] based on the presence of a diagnostic code for diabetes and the prescription of one or more glucose-lowering medications. Type 1 diabetes and other types of diabetes were excluded [23]. The analysis included new users of SGLT2i (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), commencing treatment after 1 January 2013 and with an identifiable date of type 2 diabetes diagnosis. The comparison cohort was new users of DPP4i (alogliptin, linagliptin, sitagliptin, saxagliptin, vildagliptin), as these agents represent the most commonly prescribed drug class after metformin in the UK, and have no known association

with the SGLT2i-associated AEs of interest evaluated in this study. All available follow-up data were considered in the analysis up to the point of data extraction. Individuals with a baseline HbA<sub>1c</sub> outside the range 53–120 mmol/mol (7%–13.1%) were excluded from the analysis, reflecting the threshold for glucose-lowering medication initiation in clinical guidelines and clinical guidelines for severe hyperglycaemia. Additionally, individuals with renal impairment indicated with an eGFR of less than 45 ml/min per 1.73 m<sup>2</sup> were excluded, as SGLT2i were not licensed for use below this threshold for the majority of the study period. Further exclusion criteria are summarised in Fig. 1. Our cohort was split into a population aged less than 70 years at treatment initiation and an older population (≥70 years).

Approval for the study was granted by the CPRD Independent Scientific Advisory Committee (ISCA 22\_002000).

## Outcomes

AEs included in the analysis were genital infections, micriturition control (urge incontinence, urgency, stress incontinence or nocturnal enuresis), volume depletion and dehydration, urinary frequency, falls, lower limb amputation and DKA. The occurrence of each AE was measured up to 3 years after treatment initiation and censoring of the follow-up time was implemented in case of a discontinuation of the study treatment or start of the comparison study treatment. Individuals were therefore followed up until the earliest of: date of the outcome of interest, discontinuation of the study treatment, start of comparison study treatment, date of practice deregistration/death, end of study period, or 3 years. Occurrences of AEs were identified using diagnosis code lists published at: <https://github.com/Exeter-Diabetes/CPRD-Codelists>. Genital infections were identified with either a diagnosis code for a specific genital infection (e.g. candida vaginitis or vulvo-vaginitis in women, balanitis, balanoposthitis in men), a prescription for antifungal therapy used specifically to treat genital infections (e.g. an antifungal vaginal pessary), or a non-specific diagnosis of ‘thrush’ with a topical antifungal prescribed on the same day [24]. The diagnosis codes to identify amputation AEs were taken from Pearson-Stuttard et al [25]. DKA was identified using HES hospitalisation data. Treatment outcomes to assess relative effectiveness of SGLT2i included achieved HbA<sub>1c</sub> (in mmol/mol and %) and weight (kg) on unchanged therapy. These outcome measurements were taken as the closest recorded value to 12 months post-treatment initiation, within a window of 3 to 15 months.

## Covariates

Measured covariates for all outcome models were extracted following our previous protocol [23] together with general

information about individuals, including sociodemographic features (age, sex, ethnicity and deprivation) and treatment history, important biomarkers as well as history of relevant comorbidities. Biomarker baseline values are defined nearest to treatment initiation up to 2 years before and 7 days after initiation. Initiation of relevant additional treatments, such as diuretics, have been observed up to 3 months before treatment initiation and comorbidities have been characterised to be within 1 year, 1–5 years or >5 years to treatment initiation. A summary of all covariates is given in Table 1; a cohort description and a comprehensive overview of the biomarker and comorbidity definitions are given here: <https://github.com/Exeter-Diabetes/CPRD-Cohort-scripts>.

## Statistical methods

**Causal analysis** When analysing treatment effects from observational data, bias due to confounding by indication is a major challenge. The confounding pre-treatment variables affect the outcome and the treatment decision simultaneously. As a result, it is possible that they differ in distribution between individuals who received the study treatment and comparator treatment [26]. Traditional methods such as propensity score matching can mitigate the risk of bias by adjusting for measured confounders, but they cannot control for variables that are not recorded in the data, which can lead to unmeasured confounding [26]. With the instrumental variable approach and given a suitable instrument, treatment effects can be estimated in the presence of residual or unmeasured confounding without bias [27]. The basic idea of the instrumental variable approach is that a suitable instrumental variable is used to extract variation of the treatment that is free of unmeasured confounding. This variation is then used to estimate the treatment effect [26]. We employ the advanced instrumental variable approach proposed by Ertefaie et al [28] which makes use of observed treatment behaviour and covariates to construct a proxy for prescription preference. Importantly, the method is capable of estimating the treatment effect without bias even in the presence of non-ignorable missingness in covariates. Our analysis did therefore not rely on a possibly selective complete case dataset. A more detailed explanation of this approach and a description of the assumed data structure for this study can be found in electronic supplementary material (ESM) Methods and ESM Fig. 1.

All binary AE outcomes were modelled using generalised Poisson regression with follow-up time (in days) as offset. For the estimation of the treatment effect of SGLT2i on achieved HbA<sub>1c</sub> and weight, a linear outcome model was used. Models used in the instrumental variable estimation and for all outcomes of interest were adjusted using different sets of relevant covariates specific to each outcome. A summary of all models is provided in ESM Table 1.

**Table 1** Baseline characteristics of the study cohort

Variable	SGLT2i <70 years (n=66,810)	SGLT2i ≥70 years (n=10,419)	DPP4i <70 years (n=76,172)	DPP4i ≥70 years (n=33,434)
Age, years	55.8 (8.83)	74.5 (3.81)	56.7 (8.98)	77.3 (5.37)
Sex (%)				
Male	40,863 (61.2)	6344 (60.9)	47,185 (61.9)	18,449 (55.2)
Female	25,947 (38.8)	4075 (39.1)	28,987 (38.1)	14,985 (44.8)
HbA <sub>1c</sub> , mmol/mol	77.6 (15.0)	74.8 (13.8)	74.1 (14.5)	71.0 (12.9)
HbA <sub>1c</sub> , %	9.3 (1.37)	9.0 (1.26)	8.9 (1.33)	8.6 (1.18)
eGFR, ml/min per 1.73 m <sup>2</sup>	97.1 (14.3)	80.4 (12.5)	94.1 (16.4)	73.1 (15.4)
eGFR, ml/min per 1.73 m <sup>2</sup> (%)				
45–59	548 (0.8)	590 (5.7)	2825 (3.7)	7668 (22.9)
60–89	16,886 (25.3)	6335 (60.8)	21,402 (28.1)	18,687 (55.9)
90+	49,054 (73.4)	3469 (33.3)	51,390 (67.5)	6909 (20.7)
ALT, U/l	35.6 (20.5)	27.6 (15.2)	34.8 (20.5)	24.9 (14.6)
BMI, kg/m <sup>2</sup>	34.2 (6.9)	31.6 (5.8)	32.7 (6.8)	30.0 (5.6)
Weight, kg	98.9 (22.1)	89.2 (18.3)	94.1 (21.4)	83.3 (17.5)
Insulin ever taken (%)	9326 (14.0)	1365 (13.1)	3300 (4.3)	2011 (6.0)
T2D duration, years	9.33 (6.07)	13.2 (6.99)	7.77 (5.7)	11.8 (7.4)
DPP4I type (%)				
Alogliptin			15,088 (19.8)	6901 (20.6)
Linagliptin			14,657 (19.2)	10,820 (32.3)
Saxagliptin			4507 (5.9)	1725 (5.2)
Sitagliptin			41,281 (54.2)	13,717 (41.0)
Vildagliptin			639 (0.8)	271 (0.8)
SGLT2Ii type (%)				
Canagliflozin	11,307 (16.9)	2177 (20.9)		
Dapagliflozin	30,253 (45.3)	3701 (35.5)		
Empagliflozin	25,181 (37.7)	4524 (43.4)		
Ertugliflozin	69 (0.1)	17 (0.2)		
Number of concurrent T2D treatments (%)				
1	3554 (5.3)	739 (7.1)	5877 (7.7)	5375 (16.1)
2	29,891 (44.7)	3892 (37.4)	45,043 (59.1)	18,475 (55.3)
3+	33,365 (49.9)	5788 (55.6)	25,252 (33.2)	9584 (28.7)
Number of T2D treatments ever (%)				
1	523 (0.8)	48 (0.5)	1404 (1.8)	1057 (3.2)
2	13,346 (20.0)	1282 (12.3)	32,001 (42.0)	11,886 (35.6)
3	18,475 (27.7)	2566 (24.6)	30,650 (40.2)	13,847 (41.4)
4+	34,466 (51.6)	6523 (62.6)	12,117 (15.9)	6644 (19.9)
Year of treatment initiation (%)				
2013	1127 (1.7)	127 (1.2)	9305 (12.2)	3345 (10.0)
2014	4971 (7.4)	566 (5.4)	9499 (12.5)	3539 (10.6)
2015	8910 (13.3)	1245 (11.9)	10,542 (13.8)	4290 (12.8)
2016	9805 (14.7)	1316 (12.6)	11,745 (15.4)	4959 (14.8)
2017	10,904 (16.3)	1494 (14.3)	11,659 (15.3)	5300 (15.9)
2018	12,271 (18.4)	2054 (19.7)	11,016 (14.5)	5310 (15.9)
2019	13,320 (19.9)	2542 (24.4)	9059 (11.9)	4910 (14.7)
2020	5502 (8.2)	1075 (10.3)	3347 (4.4)	1781 (5.3)
Ethnicity (%)				
White	50,321 (75.3)	9072 (87.1)	55,279 (72.6)	28,787 (86.1)
South Asian	10,172 (15.2)	791 (7.6)	12,576 (16.5)	2450 (7.3)
Black	3086 (4.6)	266 (2.6)	4580 (6.0)	1342 (4.0)


Table 1 (continued)

Variable	SGLT2i <70 years (n=66,810)	SGLT2i ≥70 years (n=10,419)	DPP4i <70 years (n=76,172)	DPP4i ≥70 years (n=33,434)
Other	1041 (1.6)	107 (1)	1348 (1.8)	299 (0.9)
Mixed	722 (1.1)	53 (0.5)	863 (1.1)	200 (0.6)
Deprivation index (%)				
1–2	10,603 (15.9)	2338 (22.5)	10,772 (14.1)	7118 (21.3)
3–4	11,380 (17.0)	2274 (21.8)	12,622 (16.6)	7001 (20.9)
5–6	12,780 (19.1)	2033 (19.5)	14,197 (18.6)	6809 (20.4)
7–8	15,272 (22.9)	2003 (19.2)	17,958 (23.6)	6622 (19.8)
9–10	16,736 (25.1)	1765 (16.9)	20,583 (27.0)	5861 (17.5)
Smoking status				
Active smoker	11,793 (17.7)	951 (9.1)	14,803 (19.4)	2968 (8.9)
Ex-smoker	35,054 (52.5)	6806 (65.3)	37,892 (49.7)	20,718 (62)
Non-smoker	17,275 (25.9)	2176 (20.9)	19,927 (26.2)	7930 (23.7)
Medication use (%)				
Loop diuretics	2428 (3.6)	997 (9.6)	3288 (4.3)	4836 (14.5)
Potassium-sparing diuretics	1185 (1.8)	314 (3.0)	1507 (2.0)	1298 (3.9)
Thiazide diuretics	7730 (11.6)	1772 (17)	9312 (12.2)	5916 (17.7)
Immunosuppressants	625 (0.9)	144 (1.4)	838 (1.1)	428 (1.3)
Oestrogens	853 (1.3)	69 (0.7)	950 (1.2)	314 (0.9)
Oral steroids	1579 (2.4)	454 (4.4)	2274 (3.0)	1993 (6.0)
Statins	48,595 (72.7)	8132 (78.0)	54,851 (72)	25,313 (75.7)
ACE inhibitors	28,655 (42.9)	4714 (45.2)	31,242 (41)	14,529 (43.5)
Comorbidities (%)				
Genital infection	34,577 (51.8)	5277 (50.6)	36,903 (48.4)	16,432 (49.1)
Urinary frequency	6530 (9.8)	1638 (15.7)	7499 (9.8)	5365 (16.0)
Micturition control	6002 (9.0)	1247 (12.0)	6866 (9.0)	5059 (15.1)
Volume depletion	5630 (8.4)	1147 (11)	6369 (8.4)	4548 (13.6)
Benign prostatic hyperplasia	2200 (3.3)	1448 (13.9)	2963 (3.9)	5057 (15.1)
Lower limb fractures	4650 (7.0)	851 (8.2)	4948 (6.5)	3061 (9.2)
Falls	7907 (11.8)	2376 (22.8)	8921 (11.7)	9300 (27.8)
Amputation	333 (0.5)	51 (0.5)	415 (0.5)	282 (0.8)
DKA	431 (0.6)	31 (0.3)	367 (0.5)	166 (0.5)
Dementia	153 (0.2)	189 (1.8)	274 (0.4)	1674 (5.0)
Cancer	3833 (5.7)	1653 (15.9)	5160 (6.8)	6415 (19.2)
Asthma	13,678 (20.5)	1962 (18.8)	14,372 (18.9)	6247 (18.7)
COPD	3684 (5.5)	1223 (11.7)	4692 (6.2)	4411 (13.2)
Heart failure	2437 (3.6)	907 (8.7)	3169 (4.2)	4141 (12.4)
CVD <sup>a</sup>	13,131 (19.7)	3841 (36.9)	15,349 (20.2)	14,067 (42.1)
Myocardial infarction	4290 (6.4)	1267 (12.2)	4998 (6.6)	4430 (13.3)
Stroke	2334 (3.5)	816 (7.8)	3145 (4.1)	3806 (11.4)
Revascularisation	4298 (6.4)	1271 (12.2)	4929 (6.5)	4135 (12.4)
Ischaemic heart disease	8320 (12.5)	2605 (25.0)	9787 (12.8)	9382 (28.1)
Angina	6141 (9.2)	1984 (19.0)	7181 (9.4)	6880 (20.6)
Peripheral arterial disease	3040 (4.6)	872 (8.4)	3548 (4.7)	3692 (11.0)
Transient ischaemic attack	1346 (2.0)	578 (5.5)	1668 (2.2)	2514 (7.5)
Chronic liver disease	8366 (12.5)	959 (9.2)	8093 (10.6)	2243 (6.7)
Osteoporosis	666 (1.0)	384 (3.7)	924 (1.2)	1920 (5.7)

Values for continuous variables are given as mean ± SD and binary and categorical variables as n (%)

<sup>a</sup>CVD: composite of myocardial infarction, stroke, revascularisation, ischaemic heart disease, angina, peripheral arterial disease, transient ischaemic attack

ALT, alanine aminotransferase; COPD, chronic obstructive pulmonary disease; T2D, type 2 diabetes



**Fig. 2** Causal effect estimation results of the IRR for AEs estimated for  $n=142,982$  participants  $<70$  ( $n=66,810$  SGLT2i,  $n=76,172$  DPP4i) and  $n=43,853$  participants  $\geq 70$  ( $n=10,419$  SGLT2i,

$n=33,434$  DPP4i). Additionally, the figure shows number ( $n$ ) of events recorded and IRs per 10,000 person-years. Values in brackets represent 95% CIs

**Sensitivity analysis** We performed the following sensitivity analyses to assess the robustness of our findings: (1) To increase power due to the low number of events for several outcomes, we defined additional composite outcomes of osmotic symptoms (comprising volume depletion/dehydration, micturition control and urinary frequency) and combined falls and lower limb fracture (as not all falls might be coded in the CPRD data and lower limb fractures are often caused by falls). Our code list for lower limb fractures excludes fractures of the foot but includes hip fractures, of which 98% are caused by a fall [29]; (2) We additionally censored individuals who switched or added any other type 2 diabetes treatments, other than the study treatments, over follow-up; (3) We repeated the analysis using 1 year maximum follow-up time for AE outcomes to assess short term risks; and (4) We excluded the second drug exposure period for individuals who initiated both treatments over the study period.

## Results

The study cohort included 186,835 episodes of participants commencing treatment with SGLT2i or DPP4i from 161,825 individuals (25,010 initiated both treatments) (Fig. 1). There


were 142,982 episodes included in the analysis for adults under 70 ( $<70$ ) ( $n=66,810$  SGLT2i,  $n=76,172$  DPP4i) and 43,853 episodes for adults 70 and older ( $\geq 70$ ) ( $n=10,419$  SGLT2i,  $n=33,434$  DPP4i). Table 1 shows the baseline characteristics of the study population by treatment arm and age group. In the supplementary material a more detailed summary of comorbidity history is provided (ESM Table 2) as well as a summary of the amount of missing data for each clinical characteristic (ESM Table 3).

Incidence rate ratio (IRR) estimates for each AE of interest are reported in Fig. 2, and person-years and mean follow-up time for all AEs are reported in ESM Table 4.

### Risk of genital infection for people with type 2 diabetes initiating SGLT2i is similarly increased in adults under and over 70

Genital infections were the most commonly recorded AE (Fig. 2), with the highest incidence in adults  $\geq 70$  commencing treatment with SGLT2i (SGLT2i incidence rate [IR] 1953.5 [95% CI 1952.8, 1954.3] per 10,000 person-years; DPP4i 956.9 [956.7, 957.2]). Causal treatment estimates suggested SGLT2i were associated with a 2.16 (1.77, 2.63) IRR of genital infection compared with DPP4i in adults  $\geq 70$ , with a similar IRR in adults under 70 (2.27 [2.03, 2.53]).

**Fig. 3** Causal effect estimation results for change in HbA<sub>1c</sub> (mmol/mol) (a) and weight (kg) (b). Point estimates represent the difference in outcome with SGLT2i compared to DPP4i, with negative values representing a greater HbA<sub>1c</sub>/weight reduction with SGLT2i over DPP4i. *n* values represent the cases with valid outcome value for which the complete case analysis is applied



**DKA is a rare AE and the risk increase with SGLT2i may be restricted to adults over 70** DKA was a rare event, and the highest IR was recorded for individuals  $\geq 70$  on SGLT2i (SGLT2i IR 29.6 [95% CI 29.5, 29.7] per 10,000 person-years; DPP4i IR 17.5 [17.5, 17.6]). Causal estimates suggested IRR for DKA with SGLT2i (compared with DPP4i) was increased for those  $\geq 70$  (IRR 3.82 [1.12, 13.03]), but not those under 70 (IRR 1.12 [0.41, 3.04]) (Fig. 2).

**Risk of osmotic AE is not increased with SGLT2i in adults under and over 70** IRs for the AE micturition control for those  $\geq 70$  taking SGLT2i was 226.6 [95% CI 226.7, 227.2] per 10,000 person-years and the causal estimates did not show an increased risk in this patient group compared with people taking DPP4i (IRR 0.81 [0.55, 1.20]). For the AE volume depletion (including dehydration), IRs in those  $\geq 70$  taking SGLT2i were 191.3 [191.1, 191.5] per 10,000 person-years. Causal estimates of risk are not increased for this group (IRR 1.00 [0.65, 1.56]). Additionally, the IR of the AE urinary frequency was 178.9 [178.7, 179.1] per 10,000 person-years and no increased risk was found for those  $\geq 70$  taking SGLT2i compared with those taking DPP4i (IRR 0.58 [0.36, 0.92]) from the causal analysis.

**Risk of falls and amputations is not increased with SGLT2i in adults under and over 70** The highest IR for falls was recorded for those  $\geq 70$  (SGLT2i IR 640.0 [95% CI 639.6, 640.3] per 10,000 person-years; DPP4i 1066.2 [1065.9, 1066.4]). Results of the causal analysis did not show evidence of an increased IRR of falls for SGLT2i in comparison with DPP4i treatment (IRR 0.86 [0.66, 1.13] for those <70 and 0.56 [0.45, 0.70] for those  $\geq 70$ ) (Fig. 2).

Lower limb amputation was rare and a higher IR was recorded for those  $\geq 70$  (SGLT2i incident rate 20.1 [95% CI 20.1, 20.2] per 10,000 person-years; DPP4i 18.3 [18.3, 18.4]). In causal analysis, there was no evidence of an increased risk of lower limb amputation (IRR 0.58 [0.22, 1.53] for those <70; 1.14 [0.29, 4.57] for those  $\geq 70$ ) (Fig. 2).

#### Glucose-lowering efficacy of SGLT2i is similar to DPP4i in older people, but in younger adults SGLT2i are more effective

Unadjusted mean HbA<sub>1c</sub> response for those <70 was  $-12.3$  mmol/mol [95% CI  $-12.4$ ,  $-12.1$ ] ( $-1.1\%$  [ $-1.1$ ,  $-1.1$ ]) on SGLT2i and  $-7.7$  mmol/mol [ $-7.8$ ,  $-7.5$ ] ( $-0.7\%$  [ $-0.7$ ,  $-0.7$ ]) in those taking DPP4i. For those  $\geq 70$ , unadjusted HbA<sub>1c</sub> response was  $-9.9$  mmol/mol [ $-10.2$ ,  $-9.5$ ] ( $-0.9\%$  [ $-0.9$ ,  $-0.9$ ]) on SGLT2i and  $-8.5$  mmol/mol [ $-8.7$ ,  $-8.4$ ] ( $-0.8\%$  [ $-0.8$ ,  $-0.8$ ]) on DPP4i. Causal estimates for differences in HbA<sub>1c</sub> response and weight change between therapies are shown in Fig. 3. For those <70, there was a greater reduction in HbA<sub>1c</sub> with SGLT2i compared with DPP4i of  $-4$  mmol/mol [ $-4.8$ ,  $-3.1$ ] ( $-0.4\%$  [ $-0.4$ ,  $-0.3$ ]). For those  $\geq 70$ , HbA<sub>1c</sub> response on both drug classes was similar (HbA<sub>1c</sub> differences between therapies  $-0.25$  mmol/mol [ $-1.63$ ,  $1.13$ ],  $-0.02\%$  [ $-0.1$ ,  $0.1$ ], favouring SGLT2i). In contrast, the causal analysis results show a greater reduction in weight with SGLT2i compared with DPP4i in both age groups, with an SGLT2i benefit of  $-2.6$  kg [ $-3.0$ ,  $-2.3$ ] for those <70 and  $-2.8$  kg [ $-3.3$ ,  $-2.3$ ] for those  $\geq 70$ . Unadjusted mean weight response was higher for participants initiating SGLT2i, with  $-3.9$  kg [ $-4.0$ ,  $-3.8$ ] for those <70 and initiating SGLT2i and  $-1.1$  kg [ $-1.1$ ,  $-1.1$ ] on DPP4i, respectively. For those  $\geq 70$ , unadjusted weight response was



−4.1 kg [−4.2, −4.0] on SGLT2i and −1.3 kg [−1.3, −1.2] on DPP4i.

**Results of the sensitivity analysis are consistent with the main causal analysis results** Results of all sensitivity analyses are given in ESM Table 5. Results were similar to the primary analysis when: (1) using composite outcomes for osmotic symptoms and falls/lower limb fractures; (2) censoring follow-up time at any change in treatment regimen; (3) restricting maximum follow-up time post-drug initiation to one year (except that DKA risk in those  $\geq 70$  was no longer significantly increased); and (4) excluding individuals initiating both treatments over the study period.

## Discussion

Our large-scale causal analysis provides important real-world evidence supporting careful use of SGLT2i in older adults. Importantly, we found no increased risk of falls, osmotic symptoms or amputations in those over 70. AEs of potential concern were genital infections and, rarely, DKA. We also demonstrate that SGLT2i are effective in reducing HbA<sub>1c</sub> in this age group, although the substantially greater glucose-lowering effect than DPP4i in younger adults with this agent is absent in the elderly, where both agents had similar efficacy.

Risk of genital infections was increased in individuals taking SGLT2i to a similar degree in both those under and over 70. This finding complements similar findings in previous meta-analysis [30] and observational data [24], which did not specifically evaluate risk in older adults. Although we found DKA risk with SGLT2i was elevated in those over 70, incidence was very low. This finding supports the warnings of the FDA [15] and the EMA [16] and stresses the need to take DKA risk factors into account when prescribing SGLT2i to older people [11, 17].

A greater mean glycaemic efficacy with SGLT2i compared with DPP4i has been consistently shown in previous RCTs [31, 32], meta-analyses [33] and observational data [34] which did not specifically evaluate older adults. We identify heterogeneity in relative glycaemic efficacy, with greater efficacy in those  $< 70$  but not in those  $\geq 70$ . This lack of glycaemic benefit with SGLT2i in older adults may relate to the association between increasing age and lower eGFR, a known predictor of attenuated glycaemic response with SGLT2i [35]. Weight reduction after SGLT2i initiation is confirmed from our results for both age-stratified populations. Previous RCT meta-analysis results comparing SGLT2i and DPP4i showed a greater weight reduction with SGLT2i of −2.45 kg [95% CI −2.71, −2.19] [5]. The extent of weight reduction in our study is similar to these results.

A major strength of our causal analysis lies in the application of the advanced instrumental variable method by Ertefaie et al [28], which addresses possible unmeasured confounding and does not rely on complete case analysis due to missingness in measured baseline characteristics. The analysis was conducted with a large real-world primary care dataset linked to hospitalisation data, capturing a broad range of AEs for SGLT2i with comprehensive primary and secondary care data.

Limitations of this study are that the analysis relies on correct clinical coding of the AEs, which can be subject to inaccuracies due to miscoding or non-coding. For example, some under-representation of genital infections might be possible as antifungal medication is available as an over-the-counter medication and can be treated without having presented to primary care. Additionally, information about the severity of the AEs was not available [24]. A limitation of the instrumental variable method is that some of the data structure assumptions made are not testable with the data. Additionally, as prescription preference was not measured in the data, our analysis relies on a proxy measurement, which might be subject to measurement errors. Previous similar instrumental variable analyses assessing relative effectiveness and risk of type 2 diabetes treatments in the CPRD data have found that the instrumental variable assumptions are reasonable in this setting [36, 37].

## Conclusion

SGLT2i in older adults are effective and do not increase risk of dehydration, falls or urinary problems in older adults with type 2 diabetes. However, risk of genital infections is increased, and DKA is a rare but severe AE of concern, meaning baseline DKA risk should be carefully assessed before initiation of SGLT2i. This study provides a valuable causal analysis framework for the study of older adults who are generally not included in randomised controlled trials.

**Supplementary Information** The online version of this article (<https://doi.org/10.1007/s00125-024-06190-9>) contains peer-reviewed but unedited supplementary material.

**Acknowledgements** This article is based on data from CPRD obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. CPRD data are provided by individuals and collected by the NHS as part of their care and support. Approval for the study was granted by the CPRD Independent Scientific Advisory Committee (ISCA 22\_002000). This study was supported by the NIHR Exeter Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The authors acknowledge contributions from the wider MASTERMIND consortium who supported this work (see ESM for a list of MASTERMIND consortium members).

**Data availability** CPRD data are available by application to the CPRD Independent Scientific Advisory Committee. R code to reproduce the

analysis in this paper is available at <https://github.com/Exeter-Diabetes/CPRD-Laura-SGLT2i-in-older-adults>.

**Funding** This research was funded by the Medical Research Council (UK) (MR/N00633X/1), and supported by EFSD/Novo Nordisk. LMG, JMD, KGY and RH are supported by Research England's Expanding Excellence in England (E3) fund. JMD is supported by a Wellcome Trust Early Career award (227070/Z/23/Z). ATH and BMS are supported by the NIHR Exeter Clinical Research Facility; the views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. AGJ was supported by an NIHR Clinician Scientist fellowship (CS-2015-15-018).

**Authors' relationships and activities** JB is a part-time employee of Novo Nordisk. This project is unrelated to his work for the company. AGJ declares research funding to his university from the UK Medical Research Council, Diabetes, JDRF and the European Foundation for the Study of Diabetes. Representatives from GSK, Takeda, Janssen, Quintiles, AstraZeneca and Sanofi attend meetings as part of the industry group involved with the MASTERMIND consortium. ERP has received honoraria for speaking from Lilly, Novo Nordisk and Illumina. No industry representatives were involved in the writing of the manuscript or analysis of data. For all authors these are outside the submitted work; there are no other relationships or activities that might bias, or be perceived to bias, their work.

**Contribution statement** LMG, APM, JMD, BMS and JB designed the study. APM, NJMT, AGJ, ERP and ATH provided valuable clinical insight and helped to interpret the results. KGY, RH, RC, ERP and APM developed code lists for the identification of relevant outcomes and comorbidities for the construction of the type 2 diabetes cohort. KGY, RH, JMD and BMS constructed the type 2 diabetes cohort of the CPRD data. From this cohort, LMG identified individuals with relevant treatment regimens and characteristics for this study. LMG, JMD, BMS and JB developed the analysis strategy. LMG analysed the data under supervision of JMD, and BMS, and with support of JB to interpret the results. LMG drafted the original version of the paper which all authors helped to edit. All authors read and approved the final version of the manuscript. APM and JMD are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

- National Institute for Health and Care Excellence (2015) Type 2 diabetes in adults: management (NG28). Available from: <https://www.nice.org.uk/guidance/ng28>. Accessed 14 March 2023
- ElSayed NA, Aleppo G, Aroda VR et al (2023) 1. Improving care and promoting health in populations: standards of care in diabetes—2023. *Diabetes Care* 46(Supplement\_1):S10–S18. <https://doi.org/10.2337/dc23-S001>
- Bradley D, Hsueh W (2016) Type 2 diabetes in the elderly: challenges in a unique patient population. *J Geriatr Med Gerontol* 2(2). <https://doi.org/10.23937/2469-5858/1510014>
- Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 43(2):487–493. <https://doi.org/10.2337/dci19-0066>
- Pinto LC, Rados DV, Remonti LR, Kramer CK, Leitao CB, Gross JL (2015) Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. *Diabetol Metab Syndr* 7(1):1–2. <https://doi.org/10.1186/1758-5996-7-S1-A58>
- Vasilakou D, Karagiannis T, Athanasiadou E et al (2013) Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. *Ann Intern Med* 159(4):262–274. <https://doi.org/10.7326/0003-4819-159-4-201308200-00007>
- Brown E, Rajeev SP, Cuthbertson DJ, Wilding JPH (2019) A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. *Diabetes Obes Metab* 21:9–18. <https://doi.org/10.1111/dom.13650>
- Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ (2016) Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. *Diabetes Obes Metab* 18(8):783–794. <https://doi.org/10.1111/dom.12670>
- Lupsa BC, Inzucchi SE (2018) Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. *Diabetologia* 61(10):2118–2125. <https://doi.org/10.1007/s00125-018-4663-6>
- Gómez-Huelgas R, Peralta FG, Mañas LR et al (2018) Treatment of type 2 diabetes mellitus in elderly patients. *Revista Clínica Española (English Edition)* 218(2):74–88
- Avogaro A, Delgado E, Lingvay I (2018) When metformin is not enough: pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. *Diabetes Metab Res Rev* 34(4):e2981. <https://doi.org/10.1002/dmrr.2981>
- Cove-Smith A, Almond MK (2007) Management of urinary tract infections in the elderly. *Trends Urol Gynaecol Sexual Health* 12(4):31–34. <https://doi.org/10.1002/tre.33>
- Sinclair AJ, Bode B, Harris S et al (2016) Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis. *J Am Geriatr Soc* 64(3):543–552. <https://doi.org/10.1111/jgs.14028>
- Goldman A, Fishman B, Twig G et al (2023) The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study. *Cardiovasc Diabetol* 22(1):16. <https://doi.org/10.1186/s12933-023-01743-5>
- U.S. Food and Drug Administration (2015) FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available from: <https://www.fda.gov/files/drugs/published/FDA-revises-labels-of-SGLT2-inhibitors-for-diabetes-to-include-warnings-about-too-much-acid-in-the-blood-and-serious-urinary-tract-infections.pdf>. Accessed 20 April 2023
- European Medicines Agency (2016) EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. Available from: <https://www.ema.europa.eu/en/medicines/human/referrals/sglt2-inhibitors>. Accessed 20 April 2023
- Scheen AJ (2021) Efficacy/safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. *Diabetes Metab* 47(6):101275. <https://doi.org/10.1016/j.diabet.2021.101275>

18. Mooradian AD (2018) Evidence-based management of diabetes in older adults. *Drugs Aging* 35:1065–1078. <https://doi.org/10.1007/s40266-018-0598-3>
19. Sinclair A, Bode B, Harris S et al (2014) Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. *BMC Endocr Disord* 14:1–11
20. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K (2013) Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. *Hosp Pract* 41(2):72–84. <https://doi.org/10.3810/hp.2013.04.1020>
21. Bode B, Stenlöf K, Harris S et al (2015) Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. *Diabetes Obes Metab* 17(3):294–303. <https://doi.org/10.1111/dom.12428>
22. Wolf A, Dedman D, Campbell J et al (2019) Data resource profile: Clinical Practice Research Datalink (CPRD) australian. *Int J Epidemiol* 48(6):1740–1740g. <https://doi.org/10.1093/ije/dyz034>
23. Rodgers LR, Weedon MN, Henley WE, Hattersley AT, Shields BM (2017) Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes. *BMJ Open* 7(10):e017989. <https://doi.org/10.1136/bmjopen-2017-017989>
24. McGovern AP, Hogg M, Shields BM et al (2020) Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. *BMJ Open Diabetes Res Care* 8(1):5
25. Pearson-Stuttard J, Cheng YJ, Bennett J et al (2022) Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records. *Lancet Diabetes Endocrinol* 10(1):46–57. [https://doi.org/10.1016/S2213-8587\(21\)00288-6](https://doi.org/10.1016/S2213-8587(21)00288-6)
26. Baiocchi M, Cheng J, Small DS (2014) Instrumental variable methods for causal inference. *Stat Med* 33(13):2297–2340. <https://doi.org/10.1002/sim.6128>
27. Davies NM, Smith GD, Windmeijer F, Martin RM (2013) COX-2 selective nonsteroidal anti-inflammatory drugs and risk of gastrointestinal tract complications and myocardial infarction: an instrumental variable analysis. *Epidemiology* 352–362. <https://doi.org/10.1097/EDE.0b013e318289e024>
28. Ertefaie A, Flory JH, Hennessy S, Small DS (2017) Instrumental variable methods for continuous outcomes that accommodate nonignorable missing baseline values. *Am J Epidemiol* 185(2):1233–1239
29. Parkkari J, Kannus P, Palvanen M et al (1999) Majority of hip fractures occur as a result of a fall and impact on the greater trochanter of the femur: a prospective controlled hip fracture study with 206 consecutive patients. *Calcif Tissue Int* 65:183–187. <https://doi.org/10.1007/s002239900679>
30. Liu J, Li L, Li S et al (2017) Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. *Scientific Reports* 7(1):2824. <https://doi.org/10.1038/s41598-017-02733-w>
31. Schernthaner G, Gross JL, Rosenstock J et al (2013) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. *Diabetes Care* 36(9):2508–2515. <https://doi.org/10.2337/dc12-2491>
32. Lavallo-González FJ, Januszewicz A, Davidson J et al (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. *Diabetologia* 56:2582–2592. <https://doi.org/10.1007/s00125-013-3039-1>
33. Schernthaner G, Lavallo-González FJ, Davidson JA et al (2016) Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. *Postgrad Med* 128(8):725–730. <https://doi.org/10.1080/00325481.2016.1210988>
34. Thayer S, Chow W, Korner S, Aguilar R (2016) Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors. *Curr Med Res Opin* 32(6):1087–1096. <https://doi.org/10.1185/03007995.2016.1159954>
35. Dennis JM, Young KG, McGovern AP et al (2022) Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. *Lancet Digit Health* 4(12):e873–e883. [https://doi.org/10.1016/S2589-7500\(22\)00174-1](https://doi.org/10.1016/S2589-7500(22)00174-1)
36. Wang PS, Schneeweiss S, Avorn J et al (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. *N Engl J Med* 353(22):2335–2341. <https://doi.org/10.1056/NEJMoa052827>
37. Bidulka P, O’Neill S, Basu A et al (2021) Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study. *BMJ Open* 11(9):9

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.